Furthermore, staining of serial sections of H292 tumors of the 510 μg groups with anti-CD166 antibody noncompeting for the antigen binding with CX-090 and anti-human IgG antibody demonstrated nearly identical staining, thus providing compelling evidence for Probody therapeutic accumulation in the tumor to be driven by the target antigen binding (Figure 5B). Here, ALCAM is linked to neoplasm.